MedTrace Logo

Combining Epigenetic And Immune Therapy to Beat Cancer.

NCT04705818 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2026-03-06

No results posted yet for this study

Summary

Umbrella study structure to independently and simultaneously assess the effects of the association of durvalumab and tazemetostat in multiple solid tumors.

Conditions

  • Advanced Solid Tumor
  • Advanced Colorectal Carcinoma
  • Advanced Soft-tissue Sarcoma
  • Advanced Pancreatic Adenocarcinoma
  • Adult Solid Tumor

Interventions

DRUG

Durvalumab

Durvalumab will be administered by intraveinous infusion (1120 mg) on day 1, every 3 weeks. Treatment by durvalumab will start on Day 22 (i.e., day 1 of cycle 2)

DRUG

Tazemetostat

Tazemetostat will be administered per-os, twice daily (800 mg x 2), continuously. Treatment by tazemetostat will start on day 1 (of cycle1).

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Epizyme, Inc.

    collaborator INDUSTRY

  • Institut Bergonié

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-23
Primary Completion
2024-01-07
Completion
2025-07-17

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04705818 on ClinicalTrials.gov